Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Use of Recombinant Human Parathyroid Hormone(1–84) in Patients with Postmenopausal Osteoporosis

(2013) Rüdiger Möricke et al.   CLINICAL DRUG INVESTIGATION

Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database

(2012) Cyrille B Confavreux et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

(2012) Volker Ziller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Health-related quality of life in patients with osteoporosis in the absence of vertebral fracture: a systematic review

(2012) S. Wilson et al.   OSTEOPOROSIS INTERNATIONAL

Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT

(2011) Philip N. Sambrook et al.   BONE

Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial

(2011) J. D. Adachi et al.   OSTEOPOROSIS INTERNATIONAL

Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial

(2011) S. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS

(2010) George Lyritis et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis

(2010) Mark J. Bolland et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Impact of Prevalent Fractures on Quality of Life: Baseline Results From the Global Longitudinal Study of Osteoporosis in Women

(2010) Jonathan D. Adachi et al.   MAYO CLINIC PROCEEDINGS

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

(2010) A. Fahrleitner-Pammer et al.   OSTEOPOROSIS INTERNATIONAL

Alendronate improves QOL of postmenopausal women with osteoporosis

(2010) Hisaya Kawate   Clinical Interventions in Aging

From Randomized Controlled Trials to Observational Studies

(2009) Stuart L. Silverman   AMERICAN JOURNAL OF MEDICINE

Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS)

(2009) Bente L. Langdahl et al.   CALCIFIED TISSUE INTERNATIONAL

Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment

(2009) Merel L Kimman et al.   Health and Quality of Life Outcomes

Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany

(2009) Renee G. Stark et al.   INFLAMMATORY BOWEL DISEASES

Improvement in health-related quality of life in osteoporosis patients treated with teriparatide

(2008) Arthur N Lau et al.   BMC MUSCULOSKELETAL DISORDERS

Sequential change in quality of life for patients with incident clinical fractures: a prospective study

(2008) H. Hagino et al.   OSTEOPOROSIS INTERNATIONAL